Adze Biotechnology
Adze Biotechnology
  • Home
  • About
  • Technology
  • Pipeline
  • Team
  • Contact Us
    • Home
    • About
    • Technology
    • Pipeline
    • Team
    • Contact Us
  • Home
  • About
  • Technology
  • Pipeline
  • Team
  • Contact Us

Oncolytic Immunotherapies For Cancer

Oncolytic Immunotherapies For Cancer

SYSTEMICALLY DELIVERABLE ONCOLYTIC IMMUNOTHERAPIES

Adze Biotechnology is developing oncolytic immunotherapies with multiple mechanisms of action that can be combined with PD-(L)1 backbones.  


Our goal is to treat tumors directly while recruiting and amplifying the patient's immune response to fight cancers.

Adze oncolytic immunotherapy payloads target immune stimulatory and inhibitory receptors on T, NK, and dendritic cells and macrophages to further amplify the immune response.


The neoantigens released from lysed cancer cells, coupled with recruited and stimulated immune cells, generate in situ systemic cancer vaccine responses, a key goal in immuno-oncology.


Adze oncolytic immunotherapies also carry their own unique PD-L1 blocking and retargeting payloads.

Chemically Shielded ADZ Single IV Treatment LNCap Tumors

image5

ADZ Single IV Dose vs Distant DU145 Prostate Tumors

image6

Prostate Tumors - Single Injection

ADZ SINGLE IV TREATMENT VS. A549 LUNG METASTASES

image7

Projected 2018 Cancer Deaths in the US

Adze oncolytic immunotherapies have the potential to treat hundreds of thousands of patients.


Copyright © 2020 Adze Biotechnology - All Rights Reserved.

  • Team